Product Information
MEXILETINE 150 MG CAPSULE is a generic product labeled by Lannett Company Inc., priced at $0.2225 per EA under NDC 00527410737. Its NADAC has been published 206 times since Oct 26, 2022.
FDA first approved this application on Jul 22, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Lannett Company Inc.NDC
00527410737
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MEXILETINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA213500FDA Approved
7/22/2020
TE Code
AB
On Market Since
7/23/2020
Pharmacological Classes
Price Statistics
The NADAC for MEXILETINE 150 MG CAPSULE has been published 206 times since Oct 26, 2022, and over the history we have for it it has declined 59.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2225 per EA |
|---|---|
| All-time high | $0.5492 (Nov 16, 2022) |
| All-time low | $0.2193 (Jul 17, 2024) |
| 52-week high | $0.2591 |
| 52-week low | $0.2225 |
| Median price | $0.2690 |
| Average price | $0.3162 |
| Largest weekly change | -34.2% (Apr 17, 2024) |
| Weeks tracked | 206 |
| Tracking since | Oct 26, 2022 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lannett Company Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mexiletine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antiarrhythmic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEXILETINE 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for MEXILETINE 150 MG CAPSULE, manufactured by Lannett Company Inc., is $0.2225 per EA (NDC 00527410737), effective Sep 30, 2026.
How has the price of MEXILETINE 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for MEXILETINE 150 MG CAPSULE has declined 59.5%. It has been tracked across 206 weekly CMS publications since Oct 26, 2022.
What are the highest and lowest recorded NADAC prices for MEXILETINE 150 MG CAPSULE?
Since Oct 26, 2022, the NADAC for MEXILETINE 150 MG CAPSULE has ranged from a low of $0.2193 (Jul 17, 2024) to a high of $0.5492 (Nov 16, 2022), with a median of $0.2690 per EA.
Are there cheaper alternatives to MEXILETINE 150 MG CAPSULE?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as MEXILETINE 150 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures MEXILETINE 150 MG CAPSULE?
MEXILETINE 150 MG CAPSULE (NDC 00527410737) is labeled by Lannett Company Inc., and CMS classifies it as a generic product.